CAROLYN ROONEY: Open Payments
NPI 1659745859 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,683 in 59 payments from 17 companies in 2025. Trend: 2023 $30 · 2024 $291 · 2025 $1,683
Food & beverage: $1,388Education: $295
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $456 |
| Regeneron Healthcare Solutions, Inc. | 8 | $328 |
| GENZYME CORPORATION | 7 | $218 |
| Galderma Laboratories, L.P. | 10 | $142 |
| SANOFI-AVENTIS U.S. LLC | 1 | $89 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $75 |
| Grifols USA, LLC | 4 | $75 |
| BioCryst US Sales Co., LLC | 2 | $69 |
| Pharming Healthcare, Inc. | 2 | $47 |
| CSL Behring | 1 | $29 |
Products named: DUPIXENT, AIRSUPRA, NEMLUVIO, BREZTRI, TEZSPIRE, NEFFY, AYVAKIT, ORLADEYO.
Industry payments across MA — which companies pay providers there.
